Thermo Fisher Scientific Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TMO research report →
About the company
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets.
- CEO
- Marc N. Casper
- IPO
- 1980
- Employees
- 125,000
- HQ
- Waltham, MA, US
Price Chart
- Market Cap
- $179.14B
- P/E
- 26.14
- P/S
- 3.96
- P/B
- 3.45
- EV/EBITDA
- 19.63
- Div Yield
- 0.37%
- Gross Margin
- 39.41%
- Op Margin
- 17.76%
- Net Margin
- 15.18%
- ROE
- 13.26%
- ROIC
- 7.33%
- Revenue
- $44.56B · 3.91%
- Net Income
- $6.74B · 6.35%
- EPS
- $17.77 · 7.18%
- Op Income
- $8.11B
- FCF YoY
- -13.40%
- 52W High
- $643.99
- 52W Low
- $385.46
- 50D MA
- $479.24
- 200D MA
- $526.46
- Beta
- 0.87
- Avg Volume
- 2.26M
Get TickerSpark's AI analysis on TMO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 20, 26 | WEISLER DION J | other | 499 |
| May 20, 26 | WEISLER DION J | other | 80.287 |
| May 20, 26 | SPERLING SCOTT M | other | 499 |
| May 20, 26 | Spar Debora L | other | 499 |
| May 20, 26 | Lynch Karen S | other | 499 |
| May 20, 26 | Keith R. Alexandra | other | 499 |
| May 20, 26 | JOHNSON JENNIFER M | other | 499 |
| May 20, 26 | Jacks Tyler | other | 499 |
| May 20, 26 | HARRIS C MARTIN | other | 499 |
| May 20, 26 | CHANDY RUBY R | other | 499 |
Our TMO coverage
Recent articles, reports, and earnings notes.
Thermo Fisher Scientific (TMO): Quality Franchise, Price Debate
Thermo Fisher Scientific remains a top-tier life sciences platform with recurring revenue, strong cash flow, and multiple growth catalysts. The stock is a Buy, but the report argues the main question is valuation rather than business quality.
The Best Healthcare Stocks Right Now (Updated June 2026)
These seven healthcare stocks combine recurring demand, identifiable franchises, and varying mixes of scale, profitability, and growth heading into June 2026.
Thermo Fisher Scientific Inc. (TMO) drops 9.2% on earnings
Thermo Fisher Scientific Inc. (TMO) drops after reporting a Q1 2026 earnings beat on revenue and EPS. Investors are focusing instead on margin pressure, mixed segment performance, and whether guidance can justify the stock’s premium valuation.
Want a deeper read on TMO?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.